RxDoctor Payments Data

Raphael Kulawik, DO

Family Medicine · Bradenton, FLNPI 1114238250

Payments from drug & device makers

$1,557in general payments, 2019–2025

Across 49 payments — averaging $31.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$545
  • Abbott$150
  • Lilly USA, LLC$144
  • Boston Scientific$115
  • Pfizer$106
  • Smith+Nephew$103
  • plus $394 from 12 others

What the payments were for

  • Speaking & faculty fees$493%
  • Food & beverage$1,50897%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,557 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$105,106
Medicare patients
215
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$21,652
MounjaroTirzepatide20$20,209
Gabapentin40$775
Atorvastatin Calcium77$695
Lisinopril76$672
LantusInsulin Glargine,hum.Rec.Anlog11$666
Rosuvastatin Calcium104$575
Albuterol Sulfate HfaAlbuterol Sulfate27$565
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$528
Levothyroxine Sodium66$501
Metoprolol Succinate44$489
Losartan Potassium74$469
Duloxetine Hcl23$455
Amlodipine Besylate87$421
Metformin Hcl82$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$21,65216 claims
Lilly USA, LLCMounjaro$144$20,20920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →